Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 10/2011

01-10-2011 | Review Article

Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer

A Systematic Review of the Literature

Authors: Gery P. Guy Jr, Dr Donatus U. Ekwueme

Published in: PharmacoEconomics | Issue 10/2011

Login to get access

Abstract

Skin cancer is the most common form of cancer in the US, and an important public health concern both in the US and throughout the world. Given high incidence rates among young adults and the large number of deaths, skin cancer has the potential to result in significant years of potential life lost (YPLL) and lost productivity. The purpose of this study was to systematically review the published literature on the YPLL and the value of productivity loss from morbidity and premature mortality resulting from melanoma and non-melanoma skin cancer (NMSC).
Employing pre-defined search terms and inclusion/exclusion criteria, systematic searches were conducted in MEDLINE, EMBASE, CINAHL and Econlit. We selected studies that measured the societal burden of melanoma and NMSC — through estimating either the YPLL and/or the indirect costs.
We identified 16 relevant studies meeting our criteria, six were from the US and ten were from other industrialized countries; ten of the studies reported results on YPLL, eight on mortality costs and five on morbidity costs. Some studies reported results in more than one category.
From each eligible article and report, we extracted detailed information on the study population/country, study design, data analysis methods and study results. Data abstracted for each eligible study included estimated number of YPLL, YPLL per death and morbidity and mortality costs. The average number of YPLL per death was approximately 15 for melanoma and 10 for NMSC. We found the costs attributable to melanoma and NMSC ranged from $US39.2 million to $US28.9 million for morbidity and $US3.3 billion to $US1.0 billion for mortality, respectively.
It is clear from the published literature that skin cancer leads to significant YPLL and indirect costs associated with premature mortality and morbidity. Prevention and early detection efforts are important in helping reduce the incidence of melanoma and NMSC, and the related deaths and productivity losses.
Literature
1.
2.
US Cancer Statistics Working Group. United States cancer statistics: 1999–2006 incidence and mortality web-based report. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2010
3.
Bleyer A, O’Leary M, Barr R, et al. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. Bethesda (MD): National Cancer Institute, 2006. NIH Pub. No. 06-5767
4.
5.
Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129 (7): 1666–74PubMedCrossRef
6.
7.
8.
9.
Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30 (5 Pt 1): 774–8PubMedCrossRef
10.
Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146 (3): 283–7PubMedCrossRef
11.
Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39 (2): 21–36PubMed
12.
Haddix AC, Teutsch SM, Corso PS. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. New York: Oxford University Press, 2003
13.
US Bureau of Labor and Statistics. Consumer price indexes. Washington, DC: Bureau of Labor Statistics, 2009 [online]. Available from URL: http://​www.​bls.​gov/​cpi [Accessed 2010 Jan 25]
14.
15.
Albert VA, Koh HK, Geller AC, et al. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990; 23 (2, pt 1): 308–10PubMedCrossRef
16.
Rainbolt T. Years of potential life lost: an evaluation of premature cancer deaths in Texas from 1981 through 1988. Tex Med 1992; 88 (1): 74–6PubMed
17.
Yabroff KR, Bradley CJ, Mariotto AB, et al. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008; 100 (24): 1755–62PubMedCrossRef
18.
Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden: and should be considered when allocating research funds. Br J Cancer 2005; 92 (2): 241–5PubMed
19.
Brochez L, Myny K, Bleyen L, et al. The melanoma burden in Belgium: premature morbidity and mortality make melanoma a considerable health problem. Melanoma Res 1999; 9 (6): 614–8PubMedCrossRef
20.
21.
Nieto A, Ruiz-Ramos M, Abdel-Kader L, et al. Gender differences in rising trends in cutaneous malignant melanoma in Spain, 1975–98. Br J Dermatol 2003; 148 (1): 110–6PubMedCrossRef
22.
Sneyd M, Cox B. The control of melanoma in New Zealand. N Z Med J 2006; 119 (1242): U2169
23.
O’Dea D. The costs of skin cancer toNew Zealand. Wellington: Wellington School of Medicine, University of Otago, 2000
24.
O’Dea D. The costs of skin cancer toNew Zealand. Wellington: Wellington School of Medicine, University of Otago, 2009
25.
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–62PubMedCrossRef
26.
Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004. A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55 (3): 490–500PubMedCrossRef
27.
Kyle JW, Hammitt JK, Lim HW, et al. Economic evaluation of the US Environmental Protection Agency’s Sun Wise program: sun protection education for young children. Pediatrics 2008 May; 121 (5): e1074–84CrossRef
28.
Morris S, Cox B, Bosanquet N. Cost of skin cancer in England. Eur J Health Econ 2009; 10 (3): 267–73PubMedCrossRef
29.
Nilsson GH, Carlsson L, Dal H, et al. Skin diseases caused by ultraviolet radiation: the cost of illness. Int J Technol Assess Health Care 2003; 19 (4): 724–30PubMedCrossRef
30.
Tinghog G, Carlsson P, Synnerstad I, et al. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol 2008; 88 (5): 467–73PubMedCrossRef
31.
Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 2008; 100 (24): 1763–70PubMedCrossRef
32.
Jemal A, Devesa SS, Hartge P, et al. Recent trends in cutabeous melanoma incidence among Whites in the United States. J Natl Cancer Inst 2001; 93 (9): 678–83PubMedCrossRef
33.
Cooke KR, Skegg DC, Fraser J. Trends in malignant melanoma of skin in New Zealand. Int J Cancer 1983; 31: 715–8PubMedCrossRef
34.
Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659–67PubMedCrossRef
35.
US Preventive Services Task Force. Screening for skin cancer. Rockville (MD): Agency for Healthcare Research and Quality, 2009
36.
Australian Cancer NetworkMelanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008
37.
Saraiya M, Glanz K, Briss P, et al. Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: a systematic review. Am J Prev Med 2004; 27 (5): 422–66PubMed
38.
Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial followup. J Clin Oncol 2011 Jan 20; 29 (3): 257–63PubMedCrossRef
39.
Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med 2008; 149 (9): 638–58PubMed
40.
Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151 (10): 738–47PubMed
41.
US Preventive Services Task Force. Screening for cervical cancer. Rockville (MD): Agency for Healthcare Research and Quality, 2003
42.
Ekwueme DU, Strebel PM, Hadler SC, et al. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000; 154 (8): 797–803PubMed
43.
Zhou F, Santoli J, Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med 2005; 159 (12): 1136–44PubMedCrossRef
44.
Carter R, Marks R, Hill D. Could a national skin cancer primary prevention campaign in Australia be worthwhile? An economic perspective. Health Promot Int 1999; 14 (1): 73–82CrossRef
45.
Shih S, Carter R, Sinclair C, et al. Economic evaluation of skin cancer prevention in Australia. Prev Med 2009; 49 (5): 449–53PubMedCrossRef
46.
Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983; 4: 129–64PubMed
47.
48.
Cockburn M, Swetter S, Peng D, et al. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 2008; 59 (6): 1081–5PubMedCrossRef
49.
Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER Medicare data. Med Care 2002; 40 (8 Suppl.): IV-104–17
50.
Bataille V, de Vries E. Melanoma — part 1: epidemiology, risk factors, and prevention. BMJ 2008; 337: a2249CrossRef
51.
Armstrong B, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63 (1-3): 8–18PubMedCrossRef
Metadata
Title
Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer
A Systematic Review of the Literature
Authors
Gery P. Guy Jr
Dr Donatus U. Ekwueme
Publication date
01-10-2011
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 10/2011
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11589300-000000000-00000

Other articles of this Issue 10/2011

PharmacoEconomics 10/2011 Go to the issue

Original Research Article

Does the Market Share of Generic Medicines Influence the Price Level?

Editorial

Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions

Review Article

A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease

Practical Application

Cautions Regarding the Fitting and Interpretation of Survival Curves

Original Research Article

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

Original Research Article

Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs